Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA. Dy GK, et al. Among authors: pitot hc. Cancer Chemother Pharmacol. 2005 Jun;55(6):522-30. doi: 10.1007/s00280-004-0950-7. Epub 2005 Mar 8. Cancer Chemother Pharmacol. 2005. PMID: 15754203 Clinical Trial.
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Adjei AA, et al. Among authors: pitot hc. J Clin Oncol. 2002 Mar 15;20(6):1683-91. doi: 10.1200/JCO.2002.20.6.1683. J Clin Oncol. 2002. PMID: 11896120 Clinical Trial.
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA. Dy GK, et al. Among authors: pitot hc. Clin Cancer Res. 2005 Mar 1;11(5):1877-83. doi: 10.1158/1078-0432.CCR-04-1769. Clin Cancer Res. 2005. PMID: 15756013 Clinical Trial.
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. Dy GK, et al. Among authors: pitot hc. Clin Cancer Res. 2005 May 1;11(9):3410-6. doi: 10.1158/1078-0432.CCR-04-2068. Clin Cancer Res. 2005. PMID: 15867242 Clinical Trial.
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C. Pitot HC, et al. Cancer Chemother Pharmacol. 2006 Aug;58(2):165-72. doi: 10.1007/s00280-005-0138-9. Epub 2005 Nov 19. Cancer Chemother Pharmacol. 2006. PMID: 16328416 Clinical Trial.
599 results